Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators

doi:10.1016/S0140-6736(08)61242-8

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators

Cardiology Division

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1174-1183
Number of pages	10
Journal	The Lancet
Volume	372
Issue number	9644
DOIs	https://doi.org/10.1016/S0140-6736(08)61242-8
State	Published - Sep 27 2008

ASJC Scopus Subject Areas

General Medicine

Access to Document

10.1016/S0140-6736(08)61242-8

OpenUrl availability

Full text

Cite this

The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators (2008). Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. The Lancet, 372(9644), 1174-1183. https://doi.org/10.1016/S0140-6736(08)61242-8

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. / The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators.
In: The Lancet, Vol. 372, No. 9644, 27.09.2008, p. 1174-1183.

Research output: Contribution to journal › Article › peer-review

The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators 2008, 'Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial', The Lancet, vol. 372, no. 9644, pp. 1174-1183. https://doi.org/10.1016/S0140-6736(08)61242-8

The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. The Lancet. 2008 Sep 27;372(9644):1174-1183. doi: 10.1016/S0140-6736(08)61242-8

The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. / Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors : a randomised controlled trial. In: The Lancet. 2008 ; Vol. 372, No. 9644. pp. 1174-1183.

@article{0414a5f169fe4294822a94cd3e96a462,

title = "Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial",

author = "{The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators} and C. Anderson and J. Pogue and L. Dyal and I. Copland and H. Schumacher and G. Dagenais and P. Sleight and B. Ramos and L. Richardson and J. Murphy and M. Haehl and L. Hilbrich and R. Svaerd and K. Martin and D. Murwin and T. Meinicke and A. Schlosser and G. Schmidt and R. Creek and M. Distel and B. Aubert and R. Schmieder and T. Unger and R. Asmar and G. Mancia and R. Diaz and E. Paolasso and L. Piegas and A. Avezum and {Cardona Munoz}, E. and J. Probstfield and M. Weber and J. Young and R. Fagard and P. Jansky and J. Mallion and J. Mann and M. B{\"o}hm and B. Eber and Karatzas, {N. B.} and M. Keltai and B. Trimarco and P. Verdecchia and A. Maggioni and Verheugt, {F. W.A.} and Holwerda, {N. J.} and L. Ceremuzynski and A. Budaj and R. Ferreira and Jacobson, {A. K.}",

note = "Funding Information: The study was supported by a grant from Boehringer Ingelheim. S Yusuf was supported by the Heart and Stroke Foundation of Ontario, and a Senior Scientist Award from the Canadian Institutes of Health Research. We thank Judy Lindeman for secretarial assistance. ",

year = "2008",

month = sep,

day = "27",

doi = "10.1016/S0140-6736(08)61242-8",

language = "English",

volume = "372",

pages = "1174--1183",

journal = "The Lancet",

issn = "0140-6736",

number = "9644",

}

TY - JOUR

T1 - Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors

T2 - a randomised controlled trial

AU - The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators

AU - Anderson, C.

AU - Pogue, J.

AU - Dyal, L.

AU - Copland, I.

AU - Schumacher, H.

AU - Dagenais, G.

AU - Sleight, P.

AU - Ramos, B.

AU - Richardson, L.

AU - Murphy, J.

AU - Haehl, M.

AU - Hilbrich, L.

AU - Svaerd, R.

AU - Martin, K.

AU - Murwin, D.

AU - Meinicke, T.

AU - Schlosser, A.

AU - Schmidt, G.

AU - Creek, R.

AU - Distel, M.

AU - Aubert, B.

AU - Schmieder, R.

AU - Unger, T.

AU - Asmar, R.

AU - Mancia, G.

AU - Diaz, R.

AU - Paolasso, E.

AU - Piegas, L.

AU - Avezum, A.

AU - Cardona Munoz, E.

AU - Probstfield, J.

AU - Weber, M.

AU - Young, J.

AU - Fagard, R.

AU - Jansky, P.

AU - Mallion, J.

AU - Mann, J.

AU - Böhm, M.

AU - Eber, B.

AU - Karatzas, N. B.

AU - Keltai, M.

AU - Trimarco, B.

AU - Verdecchia, P.

AU - Maggioni, A.

AU - Verheugt, F. W.A.

AU - Holwerda, N. J.

AU - Ceremuzynski, L.

AU - Budaj, A.

AU - Ferreira, R.

AU - Jacobson, A. K.

N1 - Funding Information: The study was supported by a grant from Boehringer Ingelheim. S Yusuf was supported by the Heart and Stroke Foundation of Ontario, and a Senior Scientist Award from the Canadian Institutes of Health Research. We thank Judy Lindeman for secretarial assistance.

PY - 2008/9/27

Y1 - 2008/9/27

UR - http://www.scopus.com/inward/record.url?scp=53049109468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53049109468&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(08)61242-8

DO - 10.1016/S0140-6736(08)61242-8

M3 - Article

C2 - 18757085

AN - SCOPUS:53049109468

SN - 0140-6736

VL - 372

SP - 1174

EP - 1183

JO - The Lancet

JF - The Lancet

IS - 9644

ER -

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

ASJC Scopus Subject Areas

Access to Document

OpenUrl availability

Other files and links

Cite this